Chief Operating Officer
Cellular Biomedicine Group
United States of America
Dr. Xia Meng has over 18 years of broad experience in biopharmaceutical and biotechnological industries, from research & development and product development to marketing, sales, business and management, both in domestic and international companies. She worked previously as General Manager of Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., and Transgene Biopharmaceutical Technology (Shanghai) Co., Ltd., Asia Pacific Scientific Director, Global Oncology Program Director, Asia Pacific Regional Business Manager of bioMérieux and Head of Fudan University Shanghai Cancer Center – Institute Mérieux Laboratory.
Dr. Meng has driven two rounds of viral vector therapeutics product development in China, and experienced all the factors of biologics development processes, such as concept, construction, pharmacology study, toxicity study, CMC, and quality control. She has conducted two successful IND applications in China, with one approved in 2004, and the other approved in 2017.